Lapaquistat-d9 acetate structure
|
Common Name | Lapaquistat-d9 acetate | ||
---|---|---|---|---|
CAS Number | 1292841-28-1 | Molecular Weight | 654.20 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C33H32D9ClN2O9 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of Lapaquistat-d9 acetateLapaquistat-d9 acetate (TAK-475-d9) is the deuterium labeled Lapaquistat acetate. Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway[1]. Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research[2]. |
Name | Lapaquistat-d9 acetate |
---|
Description | Lapaquistat-d9 acetate (TAK-475-d9) is the deuterium labeled Lapaquistat acetate. Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway[1]. Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research[2]. |
---|---|
Related Catalog | |
In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. |
References |
Molecular Formula | C33H32D9ClN2O9 |
---|---|
Molecular Weight | 654.20 |